601 264 6000
NEWSROOM

RECENT NEWS FROM HATTIESBURG CLINIC

In the Media: Rambod Rouhbakhsh, MD

Rouhbakhsh talks to Kaiser Health News about Moderna Vaccine Trial

Rambod A. Rouhbakhsh, MD, with Hattiesburg Clinic MediSync® Clinical Research, recently spoke with Kaiser Health News about the Moderna COVID-19 vaccine trial, or the COVE Study. The purpose of this study is to test an experimental vaccine that may prevent illness after exposure to the SARS-CoV-2, which causes COVID-19. The vaccine being tested in the study is called mRNA-1273.

Typical vaccines are made from a weakened or inactive virus, but the mRNA-1273 study vaccine is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid (mRNA), a genetic code that tells cells how to make protein. In this case, the protein is a small part of the virus that is thought to help the body’s immune system make antibodies to fight the virus.

The vaccine cannot cause infection or make someone sick with COVID-19. Since March 2020, more than 300 people have received the vaccine so far with no serious side effects.

Follow the link to read his comments and about trial efforts round the US: https://bit.ly/31tQScL

Tags:

Keenon Walker

Author

view all posts